Abstract: Drug-eluting beads transarterial chemoembolization (DEB-TACE) is an alternative to conventional lipiodol-based TACE (cTACE) to treat hepatocellular carcinoma (HCC). With the advancement in pharmacology, small-caliber DEB-TACE (< 100 μm) has been introduced since 2016. For the treatment of hepatic neoplasms or HCC, there is a tendency to use smaller beads by DEB-TACE to achieve more extensive tumor necrosis and a significant reduction in liver toxicity in comparison with that caused by cTACE. However, the indications and potential complications of small-caliber DEB-TACE remain uncertain and have not been well established, due to lack of randomized phase III clinical trials. Instead of systematic or meta-analysis review, this narrative review article describes the suggested indications and contraindications of DEB-TACE with small DEBs, benefit of super-selective embolization of the feeding arteries and the recommended selection of small-caliber DEB. This review was approved by the institutional review board (File Number: 1-105-05-158).

Keywords: chemoembolization, HCC, TACE, DEB-TACE, liver, review


中文翻译：

---

使用药物洗脱微珠进行经导管动脉化疗栓塞治疗肝细胞癌：小口径 (<100 μm) 微珠的推荐选择

摘要：药物洗脱微珠经动脉化疗栓塞 (DEB-TACE) 是传统基于碘油的 TACE (cTACE) 的替代疗法，可用于治疗肝细胞癌 (HCC)。随着药理学的进步，小口径DEB-TACE（<100 μm）自2016年开始被引入。对于肝肿瘤或HCC的治疗，DEB-TACE有使用更小的珠子来实现更广泛的肿瘤坏死的趋势与 cTACE 引起的肝毒性相比，肝毒性显着降低。然而，由于缺乏随机 III 期临床试验，小口径 DEB-TACE 的适应症和潜在并发症仍然不确定，尚未得到很好的确立。这篇叙述性综述文章不是系统性或荟萃分析综述，而是描述了带有小 DEB 的 DEB-TACE 的建议适应症和禁忌症，喂养动脉的超选择性栓塞和推荐选择小口径 DEB 的好处。该审查已获得机构审查委员会的批准（文件编号：1-105-05-158）。

关键词：化疗栓塞，HCC，TACE，DEB-TACE，肝脏，综述